Fullington v. Pfizer, Inc., et al., No. 12-2945 (8th Cir. 2013)Annotate this Case
In this product liability suit against the manufacturers of the prescription drug Reglan and its generic equivalent (metoclopramide), plaintiff appealed the district court's adverse grant of summary judgment to Brand Defendants and its dismissal of her claims with prejudice against Generic Defendants. The court affirmed the district court's grant of summary judgment in favor of the Brand Defendants where plaintiff's claims were not viable under Arkansas law because she stipulated that she never used Reglan manufactured or distributed by any of the Brand Defendants. In regards to the claims against the Generic Defendants, the court reversed the dismissal of plaintiff's non-warning breach of implied warranty claims and remanded for further consideration as to whether they adequately stated viable claims under Arkansas law and if so, whether the Generic Defendants could nonetheless establish preemption. It was not immediately clear whether Arkansas offered generic drug manufacturers an opportunity, consistent with federal obligations to somehow alter an otherwise unreasonably dangerous drug. Accordingly, the court affirmed the district court's dismissal of plaintiff's failure to warn and failure to update claims; reversed the dismissal of plaintiff's non-warning design defect and breach of implied warrant claims; and remanded for further proceedings.